Related Experiment Video

Updated: Jul 5, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

CD200 is induced by ERK and is a potential therapeutic target in melanoma

Kimberly B Petermann1, Gabriela I Rozenberg, Daniel Zedek

  • 1Department of Genetics, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7295, USA.

The Journal of Clinical Investigation
|November 17, 2007
PubMed

Insights

Mutations in metastatic melanoma (MM) activate ERK signaling, increasing CD200 expression. This suppresses anti-tumor immune responses by inhibiting dendritic cell (DC) function, suggesting CD200 as a therapeutic target.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Metastatic melanoma (MM) exhibits immune-mediated antitumor responses, yet immunotherapies often fail.
  • Dendritic cells (DCs) play a crucial role in activating effector cells for anti-tumor immunity.
  • Dendritic cell dysfunction may contribute to immunotherapy resistance in melanoma patients.

Purpose of the Study:

  • To investigate the role of RAS/RAF/MEK/ERK signaling in melanoma-induced immune suppression.
  • To identify downstream targets of ERK activation that impair DC function in MM.
  • To evaluate CD200 as a potential therapeutic target for overcoming immune evasion in melanoma.

Main Methods:

  • Genome-wide microarray analyses to identify downstream targets of RAS/RAF/MEK/ERK pathway.
  • Analysis of CD200 expression in melanoma cell lines and primary tumors.
  • Functional assays assessing T cell activation by DCs in the presence or absence of CD200.

Main Results:

  • Mutations in N-RAS or B-RAF in MM potently induced cell-surface CD200 expression.
  • CD200 was identified as a dynamic downstream target of RAS/RAF/MEK/ERK activation.
  • CD200 overexpression in melanoma repressed T cell activation by DCs; CD200 knockdown abrogated this effect.
  • CD200 mRNA expression correlated with melanoma progression and was higher than in other cancers.

Conclusions:

  • ERK activation in MM attenuates host anti-tumor immune response via CD200 induction.
  • Melanoma cells expressing CD200 inhibit DC-mediated T cell activation.
  • Targeting the CD200/CD200 receptor interaction presents a potential therapeutic strategy for metastatic melanoma.

More Related Videos

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...